Metformin Decreases the Adipokine Vaspin in Overweight Women With Polycystic Ovary Syndrome Concomitant With Improvement in Insulin Sensitivity and a Decrease in Insulin Resistance

OBJECTIVE—Polycystic ovary syndrome (PCOS) is associated with insulin resistance and obesity. Vaspin (visceral adipose tissue–derived serine protease inhibitor) levels increase with hyperinsulinemia and obesity. Currently, no data exists on vaspin in PCOS women. We therefore assessed mRNA and protein levels of vaspin, including circulating vaspin, from subcutaneous and omental adipose tissue of PCOS women and matched control subjects. Ex vivo regulation of adipose tissue vaspin and the effects of metformin treatment on circulating vaspin levels in PCOS subjects were also studied. RESEARCH DESIGN AND METHODS—Real-time RT-PCR and Western blotting were used to assess mRNA and protein expression of vaspin. Serum vaspin was quantified by enzyme-linked immunosorbent assay. The effects of d-glucose, insulin, and gonadal and adrenal steroids on adipose tissue vaspin were analyzed ex vivo. RESULTS—There were significantly higher levels of circulating vaspin (P < 0.05), vaspin mRNA (P < 0.05), and protein (P < 0.05) in omental adipose tissue of PCOS women. Interestingly, in omental adipose tissue explants, glucose significantly increased vaspin protein levels and secretion into conditioned media (P < 0.001). Also, after 6 months of metformin treatment, there was a significant decrease in serum vaspin levels in PCOS women (P < 0.001). Furthermore, multivariate regression analysis revealed that following metformin therapy, changes in circulating glucose levels were predictive of changes in serum vaspin levels (P = 0.014). CONCLUSIONS—We report, for the first time, elevated serum and omental adipose tissue levels of vaspin in overweight PCOS women and ex vivo regulation of vaspin, predominantly by glucose. More importantly, metformin treatment decreases serum vaspin levels, a novel observation.

[1]  G. Steinberg,et al.  Adipose tissue as an endocrine organ , 2010, Molecular and Cellular Endocrinology.

[2]  M. Fasshauer,et al.  Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes , 2008, Diabetes.

[3]  M. Fasshauer,et al.  Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. , 2008, The Journal of clinical endocrinology and metabolism.

[4]  F. Keleştimur,et al.  The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome , 2007, Clinical endocrinology.

[5]  E. Baraldi,et al.  Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia , 2007, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[6]  M. Fasshauer,et al.  Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. , 2006, Biochemical and biophysical research communications.

[7]  Eijiro Watanabe,et al.  Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[9]  B. Fauser,et al.  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.

[10]  F. Lönnqvist,et al.  A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding , 2002, International Journal of Obesity.

[11]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[12]  N. Moustaid‐Moussa,et al.  Culture of adipose tissue and isolated adipocytes. , 2001, Methods in molecular biology.

[13]  B. Wajchenberg.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. , 2000, Endocrine reviews.

[14]  A. de Leiva,et al.  Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test , 2000, Diabetologia.

[15]  G. Shulman,et al.  Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.

[16]  A. Dunaif,et al.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.

[17]  E. Ferrannini,et al.  Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production , 1994, Diabetes.

[18]  C. Sum,et al.  The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. , 1993, Metabolism: clinical and experimental.

[19]  P. Coulson,et al.  Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. , 1985, The Journal of clinical endocrinology and metabolism.